Helixate FS Articles
BioMarin completes treatment stage of rhASB trial
27 July 2001
ID Biomedical starts Ph I/II StreptAvax trial
26 July 2001
Fresenius obtains rights from Genzyme
19 July 2001
Bayer backs PPL share issue with L15 million
13 July 2001
EntreMed starts Ph I/II trial of endostatin
13 July 2001
Avigen's Coagulin-B fast-tracked in USA
13 July 2001
Promega wins in patent dispute with Roche
10 July 2001
ICOS starts trials of oral LFA-1 antagonist
5 July 2001
S-P submits FDA sBLA for Redipen system
5 July 2001
Bayer issues 2nd qtr, 2001 profit warning
27 June 2001
Wyeth fracture protein stumbles at FDA
25 June 2001
Corvas completes enrollment of rNAPc2 Phase II study
14 June 2001
Stock Commentary - Tokyo
14 June 2001
Galapagos asthma deal with Bayer
13 June 2001
Meristem and Solvay sign licensing agreement
12 June 2001
Tokyo stock comment
12 June 2001
US FDA probes counterfeit drugs
5 June 2001
EPO revokes Roche patent on PCR technology
4 June 2001
Genzyme expanding in Ireland and USA
31 May 2001
Oxxon starts melanoma vaccine trials
30 May 2001
New AHP CEO reviews growth strategy
25 May 2001
GeneMedix unveils EPO plant plans
24 May 2001
BioMarin Pharma gets $45 million boost
18 May 2001
MPS-I patients benefit from Aldurazyme
17 May 2001
Serono/Alkermes to progress r-hFSH
17 May 2001
Amgen Phase II data for rHuKGF
17 May 2001
India to permit 100% FDI in pharma sector
14 May 2001
Galapagos and UCB sign allergy deal
11 May 2001
Novo Nordisk sales climb 21%
9 May 2001
Serono makes strong start to 2001
2 May 2001
Tokyo pharma stock market: week to April 9, 2001
10 April 2001
India's CBT links with Chatterjee group
10 April 2001
New Sanofi-Synthelabo cancer drug OKed in EU
30 March 2001
Baxter appointments
29 March 2001
ImClone unveils melanoma vaccine
27 March 2001
HGS starts trials of Albuferon in HCV
26 March 2001
Baxter/Pharming start C1 inhibitor trial
12 March 2001
Stock Commentary - Tokyo
8 March 2001
Tokyo stock watch, week to March 5
7 March 2001
BioMarin Aldurazyme Ph II enrollment
2 March 2001
Eli Lilly's once-weekly Prozac gains approval from US FDA
28 February 2001
GSK plans AIDS vaccine trials later this year
23 February 2001
Novo Nordisk sales increase 27%
21 February 2001
Indian firms seek reg changes for clin trials
13 February 2001
rhATIII dropped for primary indication
8 February 2001
Aradigm and Genentech drop development of improved CF drug
6 February 2001
BioMarin gets boost as Acqua Wellington puts in $50 million
2 February 2001
Solid set of results for Chiron in 2000
1 February 2001
Ph II trials of Chiron's FGF-2 miss targets
1 February 2001
Zyprexa takes over as Eli Lilly's top seller
26 January 2001
Rebif pushes Serono sales up 16.2%
23 January 2001
US FDA gene therapy data plan: BIO fears
18 January 2001
Govt blamed for India's biotech probs
9 January 2001
Lilly seeks US approval for osteoporosis drug
8 January 2001
Healthy harvest of New Chemical Entities in 2000
2 January 2001
Stock Commentary - Europe
7 December 2000
New protein engineering firm launched in the UK
7 December 2000
Betaferon beats rivals to Japanese market
28 November 2000
Merck to seek Vioxx OK for rheumatoid arthritis
24 November 2000
Aurora Biosciences to acquire PanVera in $86 million stock deal
20 November 2000
Lilly to file for Zovant next year
17 November 2000
Allergan returns rBPI rights to Xoma
17 November 2000
Galapagos/Incyte in functional genomics accord
16 November 2000
Genentech's VEGF safe, but efficacy data are inconclusive
14 November 2000
Esperion begins first HDL-c drug trials
14 November 2000
France's Meristem takes over Sedaherb
9 November 2000
US biotech pharma market to 2004
7 November 2000
Inhale pulls plans to buy Quadrant
6 November 2000
Chiron third-quarter profits jump
1 November 2000
Genset third-quarter losses deepen
25 October 2000
New products boost growth at Eli Lilly
20 October 2000
First cancer data for Amgen's Aranesp
19 October 2000
Avonex sales disappoint in USA, according to analysts
11 October 2000
Connetics' relaxin fails Ph III scleroderma - UPDATED
10 October 2000
First clinical data for Pompe disease drug
9 October 2000
Connetics' relaxin fails Ph III scleroderma trial
9 October 2000
FDA grants first OK for Serono's Ovidrel
3 October 2000
Partial success for SB's genital herpes prophylactic vaccine, Simplirix
19 September 2000
Bayer to pay $14 mill in drug price case
19 September 2000
Bayer to pay $14 mill in drug price case
18 September 2000
Shantha plans $100 mill Nasdaq listing
18 September 2000
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
